These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24446688)

  • 1. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.
    Rosenquist Å; Samuelsson B; Johansson PO; Cummings MD; Lenz O; Raboisson P; Simmen K; Vendeville S; de Kock H; Nilsson M; Horvath A; Kalmeijer R; de la Rosa G; Beumont-Mauviel M
    J Med Chem; 2014 Mar; 57(5):1673-93. PubMed ID: 24446688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
    Xue W; Pan D; Yang Y; Liu H; Yao X
    Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
    Tsantrizos YS
    Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
    Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
    Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.
    Cummings MD; Lindberg J; Lin TI; de Kock H; Lenz O; Lilja E; Felländer S; Baraznenok V; Nyström S; Nilsson M; Vrang L; Edlund M; Rosenquist A; Samuelsson B; Raboisson P; Simmen K
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1652-5. PubMed ID: 20166108
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
    Jiang Y; Andrews SW; Condroski KR; Buckman B; Serebryany V; Wenglowsky S; Kennedy AL; Madduru MR; Wang B; Lyon M; Doherty GA; Woodard BT; Lemieux C; Geck Do M; Zhang H; Ballard J; Vigers G; Brandhuber BJ; Stengel P; Josey JA; Beigelman L; Blatt L; Seiwert SD
    J Med Chem; 2014 Mar; 57(5):1753-69. PubMed ID: 23672640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S
    Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
    Raboisson P; de Kock H; Rosenquist A; Nilsson M; Salvador-Oden L; Lin TI; Roue N; Ivanov V; Wähling H; Wickström K; Hamelink E; Edlund M; Vrang L; Vendeville S; Van de Vreken W; McGowan D; Tahri A; Hu L; Boutton C; Lenz O; Delouvroy F; Pille G; Surleraux D; Wigerinck P; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4853-8. PubMed ID: 18678486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simeprevir: a macrocyclic HCV protease inhibitor.
    Talwani R; Heil EL; Gilliam BL; Temesgen Z
    Drugs Today (Barc); 2013 Dec; 49(12):769-79. PubMed ID: 24524095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMC435 for the treatment of chronic hepatitis C.
    Tanwar S; Trembling PM; Dusheiko GM
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1193-209. PubMed ID: 22616626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.
    Flanagan S; Crawford-Jones A; Orkin C
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):691-704. PubMed ID: 25209158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.
    Lin TI; Lenz O; Fanning G; Verbinnen T; Delouvroy F; Scholliers A; Vermeiren K; Rosenquist A; Edlund M; Samuelsson B; Vrang L; de Kock H; Wigerinck P; Raboisson P; Simmen K
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1377-85. PubMed ID: 19171797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
    Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
    Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
    Lenz O; Vijgen L; Berke JM; Cummings MD; Fevery B; Peeters M; De Smedt G; Moreno C; Picchio G
    J Hepatol; 2013 Mar; 58(3):445-51. PubMed ID: 23142061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
    Raboisson P; Lin TI; Kock Hd; Vendeville S; Vreken WV; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Surleraux D; Wigerinck P; Nilsson M; Rosenquist S; Samuelsson B; Simmen K
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5095-100. PubMed ID: 18722116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
    Duan M; Kazmierski W; Crosby R; Gartland M; Ji J; Tallant M; Wang A; Hamatake R; Wright L; Wu M; Zhang YK; Ding CZ; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2993-6. PubMed ID: 22425454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.
    Liang Y; Ishida H; Lenz O; Lin TI; Nyanguile O; Simmen K; Pyles RB; Bourne N; Yi M; Li K; Lemon SM
    Gastroenterology; 2008 Nov; 135(5):1710-1718.e2. PubMed ID: 18725224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.
    Scola PM; Wang AX; Good AC; Sun LQ; Combrink KD; Campbell JA; Chen J; Tu Y; Sin N; Venables BL; Sit SY; Chen Y; Cocuzza A; Bilder DM; D'Andrea S; Zheng B; Hewawasam P; Ding M; Thuring J; Li J; Hernandez D; Yu F; Falk P; Zhai G; Sheaffer AK; Chen C; Lee MS; Barry D; Knipe JO; Li W; Han YH; Jenkins S; Gesenberg C; Gao Q; Sinz MW; Santone KS; Zvyaga T; Rajamani R; Klei HE; Colonno RJ; Grasela DM; Hughes E; Chien C; Adams S; Levesque PC; Li D; Zhu J; Meanwell NA; McPhee F
    J Med Chem; 2014 Mar; 57(5):1708-29. PubMed ID: 24555570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.